Abstract
Introduction: Tumor molecular profiling has proven relevant for the clinical
management of cancer. Circulating tumor DNA (ctDNA) may be a useful
surrogate of tumor tissue when this is insufficient for analysis. Aim(s): Aims:
Rate of test failure, detection rate of pathological alterations (PAs) and impact
on management. Materials and methods: Patients (pts) with welldifferentiated neuroendocrine tumors (WdNETs) underwent ctDNA-based
molecular profiling (FoundationLiquid®); non-WdNETs (paraganglioma, goblet
cell or poorly differentiated neuroendocrine carcinoma) were used for
comparison. Results: Fifteen pts with WdNET (18 ctDNA samples) included: 8
female (53.33%), median age 63.2 years (range 23.5-86.8). Primary: small
bowel (8;53.3%); pancreas (5;33.3%); gastric (1;6.7%) and unknown primary
(1;6.7%); grade (G)1 (n=5;33.3%); G2 (9;60.0%) and G3 (1;6.7%); median Ki67: 5% (range 1-30). Thirty pts with non-WdNETs pts (34 ctDNA samples)
were included. Five WdNETs samples (27.78%) failed analysis (vs 17.65% in
non-WdNETs; p 0.395). Of 13 WdNET samples with successful ctDNA, PAs
were detected in 6 (46.15%) (vs 82.14% in non-WdNETs; p 0.018). In
WdNETs, PA rate was independent of anti-cancer systemic therapy
(2/7;28.57% vs 4/6;66.67%; p 0.286) at time of ctDNA: 4, 1 and 1 samples had
1, 2 and 3 PAs, respectively; these were: CDKN2A mutation (m) (1 sample),
CHEK2m (1), TP53m (2), FGFR2amplif (1), IDH2m (1), CTNNB1m (1), NF1m
(1), PALB2m (1); nontargetable (0%) or impacted management (0%). There
was a trend towards lower maximum mutant allele frequency (mMAF) in
WdNETs (mean 0.33) vs non-WdNETs (mean 26.99); p 0.0584. Conclusion:
Although feasible, ctDNA molecular profiling was of limited clinical utility for
advanced WdNETs. Identification of PAs and mMAF seem higher in nonWdNETs.
management of cancer. Circulating tumor DNA (ctDNA) may be a useful
surrogate of tumor tissue when this is insufficient for analysis. Aim(s): Aims:
Rate of test failure, detection rate of pathological alterations (PAs) and impact
on management. Materials and methods: Patients (pts) with welldifferentiated neuroendocrine tumors (WdNETs) underwent ctDNA-based
molecular profiling (FoundationLiquid®); non-WdNETs (paraganglioma, goblet
cell or poorly differentiated neuroendocrine carcinoma) were used for
comparison. Results: Fifteen pts with WdNET (18 ctDNA samples) included: 8
female (53.33%), median age 63.2 years (range 23.5-86.8). Primary: small
bowel (8;53.3%); pancreas (5;33.3%); gastric (1;6.7%) and unknown primary
(1;6.7%); grade (G)1 (n=5;33.3%); G2 (9;60.0%) and G3 (1;6.7%); median Ki67: 5% (range 1-30). Thirty pts with non-WdNETs pts (34 ctDNA samples)
were included. Five WdNETs samples (27.78%) failed analysis (vs 17.65% in
non-WdNETs; p 0.395). Of 13 WdNET samples with successful ctDNA, PAs
were detected in 6 (46.15%) (vs 82.14% in non-WdNETs; p 0.018). In
WdNETs, PA rate was independent of anti-cancer systemic therapy
(2/7;28.57% vs 4/6;66.67%; p 0.286) at time of ctDNA: 4, 1 and 1 samples had
1, 2 and 3 PAs, respectively; these were: CDKN2A mutation (m) (1 sample),
CHEK2m (1), TP53m (2), FGFR2amplif (1), IDH2m (1), CTNNB1m (1), NF1m
(1), PALB2m (1); nontargetable (0%) or impacted management (0%). There
was a trend towards lower maximum mutant allele frequency (mMAF) in
WdNETs (mean 0.33) vs non-WdNETs (mean 26.99); p 0.0584. Conclusion:
Although feasible, ctDNA molecular profiling was of limited clinical utility for
advanced WdNETs. Identification of PAs and mMAF seem higher in nonWdNETs.
| Original language | English |
|---|---|
| Publication status | Published - 2021 |
| Event | 18th Annual ENETs conference - Duration: 25 Feb 2021 → 27 Feb 2021 |
Conference
| Conference | 18th Annual ENETs conference |
|---|---|
| Period | 25/02/21 → 27/02/21 |
Keywords
- ctDNA
- Well-differentiated
- neuroendocrine
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre
